Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-112574·Atara Biotherapeutics, Inc.
Schedule 13D ownership disclosure
Atara Biotherapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 046513206
Event date: 2025-11-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Redmile Group, LLCReported CIK 0001425738
Shares: 751,223.00 · Class: 9.9%
- Jeremy C. GreenReported CIK 0001650527
Shares: 751,223.00 · Class: 9.9%
- RedCo I, L.P.Reported CIK 0001813157
Shares: 347,442.00 · Class: 4.7%
- Redmile Biopharma Investments II, L.P.Reported CIK 0001772230
Shares: 452,153.00 · Class: 6.0%
- Redmile Strategic Long Only Trading Sub, Ltd.Reported CIK 0002048243
Shares: 376,377.00 · Class: 5.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-112574
- Form type
- SCHEDULE 13D/A
- Filer
- Atara Biotherapeutics, Inc.
- CIK
- CIK 1604464
- Filed
- Nov 14, 2025
- Reporting period
- Nov 12, 2025
- Description
- Schedule 13D beneficial ownership